Roles and mechanisms of renalase in cardiovascular disease: A promising therapeutic target

Biomed Pharmacother. 2020 Nov:131:110712. doi: 10.1016/j.biopha.2020.110712. Epub 2020 Sep 9.

Abstract

Cardiovascular disease (CVD) is prevalent worldwide and remains a leading cause of death. Although substantial progress has been made in the diagnosis and treatment of CVD, the prognosis remains unsatisfactory. Renalase is a newly discovered cytokine that is synthesized by the kidney and then secreted into blood. Numerous studies have suggested the efficacy of renalase in treating CVD by metabolizing catecholamines in the circulatory system. As a new biomarker of heart disease, renalase is normally recognized as a signalling molecule that activates cytoprotective intracellular signals to lower blood pressure, protect ischaemic heart muscle and promote atherosclerotic plaque stability in CVD, which subsequently improves cardiac function. Due to its important regulatory role in the circulatory system, renalase has gradually become a potential target in the treatment of CVD. This review summarizes the structure, mechanism and function of renalase in CVD, thereby providing preclinical evidence for alternative approaches and new prospects in the development of renalase-related drugs against CVD.

Keywords: Cardiovascular disease; Chronic kidney disease; Drug target; Mechanism; Renalase.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / etiology*
  • Coronary Artery Disease / etiology
  • Heart Failure / etiology
  • Humans
  • Hypertension / etiology
  • Monoamine Oxidase / chemistry
  • Monoamine Oxidase / physiology*
  • Monoamine Oxidase / therapeutic use

Substances

  • Monoamine Oxidase
  • renalase